LONDON, Dec 2 (Reuters) – Britain’s healthcare
cost-effectiveness watchdog NICE has recommended use of Merck’s
immunotherapy drug Keytruda in certain lung cancer
patients, after the U.S. drugmaker…
The post Merck wins UK okay for Keytruda in lung cancer after price cut appeared first on NASDAQ.